PR Newswire
ROCKVILLE, Md.
and
BEIJING
,
Nov. 2, 2021
/PRNewswire/ — CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing the third quarter highlights at
8:00 a.m. EDT on Friday
, November 12
th
, 2021.
On the call, CASI’s Chairman & CEO will provide an update on the Company’s business and upcoming milestones. The conference call can be accessed by dialing 1-877-870-4263 (U.S.) or 1-412-317-0790 (international) and ask to be joined into the CASI Pharmaceuticals call to listen to the live conference call.
This call will be recorded and available for replay by dialing 1-877-344-7529 (U.S.) or 1-412-317-0088 (international) and enter 10160251 to access the replay.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in
China
,
the United States
, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the greater
China
market leveraging the Company’s
China
-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in
China
are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (
China
) Co., Ltd., which is located in
Beijing, China
. The Company has built a commercial team of more than 100 hematology-oncology sales and marketing specialists based in
China
. More information on CASI is available at
www.casipharmaceuticals.com
.
|
|
|
View original content to download multimedia:
https://www.prnewswire.com/news-releases/casi-pharmaceuticals-to-report-third-quarter-2021-financial-results-and-host-conference-call-november-12-2021-301413396.html
SOURCE CASI Pharmaceuticals, Inc.
